PeterMartinMD

Hematologic Oncology

Associate Professor, Medicine, Weill Cornell Medicine

Overview of Dr. Martin

I take care of people with lymphoma. I don't rush, I listen. Together we will develop the plan that is best. At the Weill Cornell Lymphoma Program, one of the most experienced teams in the country, we work along side experts in every field of medicine to care for the whole person.

As Chief of the Lymphoma Program, I know that our group is working tirelessly to develop better treatments and integrate them into clinical practice. We have been involved in the development of virtually every drug approved for treatment of lymphoma over the past 15 years, including targeted therapies and immunotherapy. We have made a lot of progress, and we are not stopping to rest.

Office
520 E 70th St
# Starr
New York, NY 10021
Book by Phone+1(234) 595-2008

Fax+1 646-962-1605

Education & Training

McGill UniversityFellowship in Hematology, 2004 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2001 - 2004
University of AlbertaClass of 2001
Cornell UniversityMS

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 2009 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies Start of enrollment: 2007 Jun 01
Completed
Phase 1
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL) Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma Start of enrollment: 2010 Oct 01
Terminated
Phase 1, Phase 2
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies Start of enrollment: 2010 Dec 01
Completed
Phase 2
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma Start of enrollment: 2011 Oct 20
Completed
Phase 2
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2011 Dec 06
Completed
Phase 2
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia Start of enrollment: 2012 Jun 01
Terminated
Phase 2
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Start of enrollment: 2013 Dec 01
Completed
Phase 2
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma Start of enrollment: 2014 May 20
Active, not recruiting
Phase 1
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Start of enrollment: 2014 Nov 01
Recruiting
Phase 2
A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma Start of enrollment: 2015 Apr 29
Completed
Phase 1
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma Start of enrollment: 2015 Dec 11
Completed
Phase 1
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Start of enrollment: 2015 Jul 01
Withdrawn
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2016 Jun 20
Active, not recruiting
Phase 2
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma Start of enrollment: 2018 Nov 28
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.
Paolo Strati, Rebecca Champion, Morton Coleman, Sonali M Smith, Parameswaran Venugopal
British Journal of Haematology. 2024-12-01
2 citations
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Mitchell R Smith, Opeyemi A Jegede, Peter Martin, Brian G Till, Samir S Parekh
Blood. 2024-09-05
1 citations
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
Arushi Khurana, Raphael Mwangi, Loretta J Nastoupil, Patrick M Reagan, Umar Farooq
Blood Advances. 2024-08-27

Abstracts/Posters

T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL)
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as...
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
An Assessment of Race As a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B Cell Lymphoma
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Peter Martin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Press Mentions

Who Qualifies for a Coronavirus Booster Shot? Why It’s Still UnclearAugust 13th, 2021
The Complex Situation for Immunocompromised People and COVID-19 VaccinesJune 16th, 2021
Assessing Response to Follicular Lymphoma TreatmentSeptember 24th, 2020
Join now to see all

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member

Other Languages

Spanish, French

Insurance Accepted

Aetna Choice POS II
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Healthfirst New York
Humana ChoiceCare Network PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment